June 22, 2017Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
Newly Published Preclinical Data Demonstrate the Potential of IONIS-KRAS-2.5Rx in Cancer
Nature Communications Publishes Preclinical Results Evaluating Antisense Drugs Targeting DNM2 for the Treatment of Centronuclear Myopathy
Newly Published Data Characterizes the Burden of Disease in Patients with Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals’ CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »
No upcoming events at this time...